A detailed history of China Universal Asset Management Co., Ltd. transactions in Hutchmed (China) LTD stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 5,966 shares of HCM stock, worth $85,313. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,966
Previous 3,645 63.68%
Holding current value
$85,313
Previous $62,000 87.1%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$16.03 - $20.31 $37,205 - $47,139
2,321 Added 63.68%
5,966 $116,000
Q2 2024

Jul 19, 2024

SELL
$16.36 - $21.78 $37,431 - $49,832
-2,288 Reduced 38.56%
3,645 $62,000
Q1 2024

Apr 29, 2024

BUY
$12.08 - $18.56 $28,267 - $43,430
2,340 Added 65.13%
5,933 $100,000
Q4 2023

May 21, 2024

SELL
$16.25 - $20.23 $38,025 - $47,338
-2,340 Reduced 39.44%
3,593 $65,000
Q4 2023

Jan 23, 2024

BUY
$16.25 - $20.23 $45,516 - $56,664
2,801 Added 353.66%
3,593 $65,000
Q3 2023

May 21, 2024

BUY
$11.85 - $16.95 $4,503 - $6,441
380 Added 92.23%
792 $13,000
Q3 2023

Oct 30, 2023

BUY
$11.85 - $16.95 $4,503 - $6,441
380 Added 92.23%
792 $13,000
Q2 2023

May 21, 2024

SELL
$10.78 - $17.73 $463 - $762
-43 Reduced 9.45%
412 $4,000
Q2 2023

Jul 27, 2023

SELL
$10.78 - $17.73 $463 - $762
-43 Reduced 9.45%
412 $5,000
Q1 2023

May 21, 2024

BUY
$13.02 - $19.87 $1,041 - $1,589
80 Added 21.33%
455 $5,000
Q1 2023

Apr 27, 2023

BUY
$13.02 - $19.87 $1,041 - $1,589
80 Added 21.33%
455 $6,000
Q4 2022

May 21, 2024

SELL
$7.65 - $15.51 $42,518 - $86,204
-5,558 Reduced 93.68%
375 $5,000
Q4 2022

Jan 31, 2023

BUY
$7.65 - $15.51 $122 - $248
16 Added 4.46%
375 $6,000
Q3 2022

Oct 21, 2022

BUY
$8.63 - $15.52 $3,098 - $5,571
359 New
359 $3,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.